Travere Therapeutics, Inc.TVTXEarnings & Financial Report
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
TVTX Q4 FY2025 Key Financial Metrics
Revenue
$129.7M
Gross Profit
$127.1M
Operating Profit
$-32.4M
Net Profit
N/A
Gross Margin
98.0%
Operating Margin
-25.0%
Net Margin
N/A
YoY Growth
73.4%
EPS
$0.04
Travere Therapeutics, Inc. Q4 FY2025 Financial Summary
Travere Therapeutics, Inc. reported revenue of $129.7M (up 73.4% YoY) for Q4 FY2025, with a net profit of N/A (N/A margin). Cost of goods sold was $2.6M, operating expenses totaled $159.6M.
Key Financial Metrics
| Total Revenue | $129.7M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 98.0% |
| Operating Margin | -25.0% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Travere Therapeutics, Inc. Q4 FY2025 revenue of $129.7M breaks down across 3 segments, led by FILSPARI at $103.3M (79.7% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| FILSPARI | $103.3M | 79.7% |
| Tiopronin Products | $23.3M | 17.9% |
| License | $3.1M | 2.4% |
Travere Therapeutics, Inc. Revenue by Segment — Quarterly Trend
Travere Therapeutics, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as FILSPARI and Tiopronin Products) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| FILSPARI | $103.3M | $90.9M | $71.9M | $55.9M |
| Tiopronin Products | $23.3M | $22.3M | $23.0M | $20.0M |
| License | $3.1M | $51.7M | $19.6M | $5.9M |
Travere Therapeutics, Inc. Annual Revenue by Year
Travere Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $490.7M).
Travere Therapeutics, Inc. Quarterly Revenue & Net Profit History
Travere Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $129.7M | +73.4% | N/A | N/A |
| Q3 FY2025 | $164.9M | +162.1% | $25.7M | 15.6% |
| Q2 FY2025 | $114.4M | +111.5% | $-12.8M | -11.1% |
| Q1 FY2025 | $81.7M | +97.5% | $-41.2M | -50.4% |
| Q4 FY2024 | $74.8M | +66.0% | N/A | N/A |
| Q3 FY2024 | $62.9M | +69.6% | $-54.8M | -87.1% |
| Q2 FY2024 | $54.1M | +68.1% | $-70.4M | -130.1% |
| Q1 FY2024 | $41.4M | +33.9% | $-136.1M | -328.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $41.4M | $54.1M | $62.9M | $74.8M | $81.7M | $114.4M | $164.9M | $129.7M |
| YoY Growth | 33.9% | 68.1% | 69.6% | 66.0% | 97.5% | 111.5% | 162.1% | 73.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $663.5M | $551.1M | $504.4M | $594.1M | $548.8M | $555.3M | $538.6M | $605.2M |
| Liabilities | $589.5M | $536.0M | $534.9M | $535.0M | $516.0M | $522.6M | $465.0M | $490.4M |
| Equity | $74.1M | $15.1M | $-30.5M | $59.1M | $32.8M | $32.7M | $73.6M | $114.8M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-119.0M | $-40.2M | $-42.5M | $-35.7M | $-42.2M | $5.0M | $14.3M | $60.7M |